Exogenous and endogenous hormones and breast cancer

被引：76

作者：

Chen, Wendy Y. ^{[1
,2
]}

机构：

[1] Harvard Univ, Sch Med, Channing Lab, Brigham & Womens Hosp, Boston, MA 02115 USA

[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

来源：

BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM | 2008年 / 22卷 / 04期

关键词：

breast cancer; hormone replacement therapy; estrogen; sex steroids;

D O I：

10.1016/j.beem.2008.08.001

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Exposure to higher levels of both exogenous and endogenous hormone is associated with breast cancer risk. Because of the association between breast cancer and HRT, only the minimal duration of HRT use is recommended for symptom control, and it is not recommended for chronic disease management. Current research issues include the role of progestins, other types of HRT duration of unopposed estrogen use, and characteristics of cancers that develop on HRT Circulating sex steroid levels are associated with breast cancer risk, but multiple issues need to be addressed before they are used routinely in clinical practice. Current research issues include measurement of levels for routine clinical practice, integration with standard breast cancer risk models and genetic polymorphism data, and applicability to estrogen-receptor-negative cancers.

引用

页码：573 / 585

页数：13

共 52 条

[1]

*AM COLL OBST GYN, 2004, OBSTET GYNECOL S, V104, pS1

[2]

Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial [J].

Anderson, GL ;

Limacher, M ;

Assaf, AR ;

Bassford, T ;

Beresford, SAA ;

Black, H ;

Bonds, D ;

Brunner, R ;

Brzyski, R ;

Caan, B ;

Chlebowski, R ;

Curb, D ;

Gass, M ;

Hays, J ;

Heiss, G ;

Hendrix, S ;

Howard, BV ;

Hsia, J ;

Hubbell, A ;

Jackson, R ;

Johnson, KC ;

Judd, H ;

Kotchen, JM ;

Kuller, L ;

LaCroix, AZ ;

Lane, D ;

Langer, RD ;

Lasser, N ;

Lewis, CE ;

Manson, J ;

Margolis, K ;

Ockene, J ;

O'Sullivan, MJ ;

Phillips, L ;

Prentice, RL ;

Ritenbaugh, C ;

Robbins, J ;

Rossouw, JE ;

Sarto, G ;

Stefanick, ML ;

Van Horn, L ;

Wactawski-Wende, J ;

Wallace, R ;

Wassertheil-Smoller, S .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14) :1701-1712

[3]

Beatson GT., 1896, LANCET, V148, P104, DOI DOI 10.1016/S0140-6736(01)72307-0

[4]

Endogenous sex hormones, breast cancer risk, and tamoxifen response: An ancillary study in the NSABP Breast Cancer Prevention Trial (P-1) [J].

Beattie, MS ;

Costantino, JP ;

Cummings, SR ;

Wickerham, DL ;

Vogel, VG ;

Dowsett, M ;

Folkerd, EJ ;

Willett, WC ;

Wolmark, N ;

Hankinson, SE .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (02) :110-115

[5]

Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0

[6]

Beral Valerie, 2003, Lancet, V362, P419, DOI 10.1016/S0140-6736(03)14065-2

[7]

Intratumoral levels of estrogens in breast cancer [J].

Blankenstein, MA ;

van de Ven, J ;

Maitimu-Smeele, I ;

Donker, GH ;

de Jong, PC ;

Daroszewski, J ;

Szymczak, J ;

Milewicz, A ;

Thijssen, JHH .

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1999, 69 (1-6) :293-297

[8]

Bone mineral density and risk of breast cancer in older women - The study of osteoporotic fractures [J].

Cauley, JA ;

Lucas, FL ;

Kuller, LH ;

Vogt, MT ;

Browner, WS ;

Cummings, SR .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (17) :1404-1408

[9]

Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer [J].

Chen, Wendy Y. ;

Colditz, Graham A. .

NATURE CLINICAL PRACTICE ONCOLOGY, 2007, 4 (07) :415-423

[10]

Unopposed estrogen therapy and the risk of invasive breast cancer [J].

Chen, WY ;

Manson, JE ;

Hankinson, SE ;

Rosner, B ;

Holmes, MD ;

Willett, WC ;

Colditz, GA .

ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (09) :1027-1032

← 1 2 3 4 5 6 →